.. BioMedReports.Com’s news statement on CEL-SCI’s key developments BioMedReports.Com, the news headlines portal which covers Wall structure Street’s biomedical sector and delivers financial and expenditure cleverness to a community of highly informed traders, has issued a particular news report on important developments at CEL-SCI Company . Related StoriesCornell biomedical engineers develop 'super organic killer cells' to destroy cancers cells in lymph nodesNew antenna-like device makes breasts cancer surgery much easier for surgeonsFDA grants accelerated acceptance for Tagrisso to take care of individuals with advanced NSCLCFor better or even worse, news of the business’s novel H1N1 flu treatment for already contaminated patients offers pushed CEL-SCI to 1 of the heaviest exchanged sectors in the biotech marketplace.This collaboration contains support for 5 full-time research scientists and builds on the scientific pharmacology fellowship programme announced by CRT and The University of Manchester on 20 November 2006. Related StoriesFDA grants accelerated acceptance for Tagrisso to take care of patients with advanced NSCLCMeat-rich diet may increase kidney cancers riskMD Anderson research reveals why chemotherapy drugs not effective for most pancreatic cancer patientsWithin the alliance the Clinical and Experimental Pharmacology Group, led by Professor Caroline Dive and Dr Malcolm Ranson jointly, will provide leading edge expertise in PD assay implementation and development. The group specialises in using immunohistochemical, flow ELISA-based and cytometric techniques to progress and validate biomarkers linked to cancer.